RELATIVE LIPOPHILICITIES, SOLUBILITIES, AND STRUCTURE PHARMACOLOGICAL CONSIDERATIONS OF 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A (HMG-COA) REDUCTASE INHIBITORS PRAVASTATIN, LOVASTATIN, MEVASTATIN, AND SIMVASTATIN

被引:195
作者
SERAJUDDIN, ATM
RANADIVE, SA
MAHONEY, EM
机构
[1] Bristol-Myers Squibb Pharmaceutical Research Institute, New Brunswick, New Jersey
关键词
D O I
10.1002/jps.2600800905
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The apparent octanol-water partition coefficients (P(o/w)) and aqueous solubilities for four 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors [pravastatin, lovastatin (mevinolin), mevastatin (compactin), and simvastatin (synvinolin)] were compared. Pravastatin is highly hydrophilic compared with lovastatin, mevastatin, or simvastatin. Pravastatin is clinically used as the active hydroxy acid, while the other three compounds are administered as prodrug lactones which, over a period of time, convert in vivo to their respective active hydroxy acid forms. The order of the P(o/w) values of the hydroxy acid forms was pravastatin << mevastatin < lovastatin < simvastatin at each pH evaluated, with approximate ratios of 1:25:75:200, respectively. The relative order and the ratios of partition coefficients for the lactone forms were similar to those for the hydroxy acid forms. In addition, lovastatin, mevastatin, and simvastatin are virtually insoluble in water, with solubility values ranging from 0.0013 to 0.0015 mg/mL at 23-degrees-C. In comparison, pravastatin is hydrophilic, as demonstrated by the > 100-fold greater solubility of its lactone form (0.18 mg/mL). The greater hydrophilicity of pravastatin may explain its reported lower permeation into nonhepatic cells and the selectivity with respect to inhibition of cholesterol synthesis.
引用
收藏
页码:830 / 834
页数:5
相关论文
共 24 条
[1]  
ABERNETHY DR, 1985, AM HEART J, V5, P1120
[2]   PHARMACOKINETICS, CENTRAL NERVOUS-SYSTEM UPTAKE, AND LIPID SOLUBILITY OF PROPRANOLOL, ACEBUTOLOL, AND SOTALOL [J].
ARENDT, RM ;
GREENBLATT, DJ ;
DEJONG, RH ;
BONIN, JD ;
ABERNETHY, DR .
CARDIOLOGY, 1984, 71 (06) :307-314
[3]  
BARTH JD, 1989, 10 INT S DRUG AFF LI
[4]   BETA-BLOCKING DRUGS AND SLEEP - A CONTROLLED TRIAL [J].
BETTS, TA ;
ALFORD, C .
DRUGS, 1983, 25 :268-272
[5]  
DOBRINSKA MR, 1988, PHARMACOL RES S, V5, P182
[6]  
DUGGAN DE, 1989, DRUG METAB DISPOS, V17, P166
[8]   TISSUE SELECTIVITY OF THE CHOLESTEROL-LOWERING AGENTS LOVASTATIN, SIMVASTATIN AND PRAVASTATIN IN RATS INVIVO [J].
GERMERSHAUSEN, JI ;
HUNT, VM ;
BOSTEDOR, RG ;
BAILEY, PJ ;
KARKAS, JD ;
ALBERTS, AW .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1989, 158 (03) :667-675
[9]  
GRUNDY SM, 1988, NEW ENGL J MED, V319, P24
[10]  
HENNINGSEN NC, 1979, ACTA MED SCAND, V205, P61